Access all of the content
It was a pleasure to be able to speak with John Stone (Massachusetts General Hospital, Boston, MA, USA) about the findings from his investigations into tocilizumab as a therapy for COVID-19 infection.
His presentation entitled ‘Tocilizumab for COVID-19 Infection: A Randomized, Double-Blind, Placebo-Controlled Trial’ (Abstract Number: L07) was presented at the ACR Convergence, 5-9 November.
- What is the rationale for the use of tocilizumab for COVID-19 infection? (0:16)
- What is the rationale for the use of tocilizumab for COVID-19 infection? (1:40)
- What might explain tocilizumab’s lack of efficacy in this treatment setting? (3:07)
- How do these findings compare with other studies of tocilizumab for COVID-19 infection? (4:32)
- Is tocilizumab likely to play any role in the treatment of COVID-19 outcomes? (5:20)
Disclosures: John H. Stone has received research funding from Roche, Principia, Viela Bio and Bristol Myers Squibb; and consulting fees from Roche, Principia, Viela Bio, Bristol Myers Squibb, Sanofi, Chemocentryx, Celgene, Abbvie, Chugai, Grunenthal, Glaxo Smith Kline, Infla Rx, Insmed, Regeneron, Roivant, Q32 bio, and SpruceBiosciences.
Support: Interview and filming supported by Touch Medical Media Ltd.
Filmed in coverage of virtual ACR Convergence 2020.
Share this Video
Related Videos In COVID-19
Stavros Dimitriadis, EASL ILC 2022: Immune responses to fourth COVID-19 vaccination in liver transplant recipients and patients with autoimmune hepatitis
In some countries, patients considered vulnerable have received 3rd/4th COVID-19 vaccine doses (V3/V4). This study, presented by Stavros Dimitriadis (University of Oxford, Oxford, UK), explores the immune response to V4 in a mixed disease cohort of immunosuppressed patients including liver transplant recipients and patients with autoimmune hepatitis. This study also focused on individuals with absent […]
James Alexander, ECCO-IBD 2022: COVID-19 Vaccination in Patients with IBD on Immunosuppressants
We caught up with Dr James Alexander (Imperial College London, London, UK) to discuss the impact of immunosuppressant drugs on COVID-19 vaccine responses in patients with IBD. The abstract ‘COVID-19 vaccine-induced antibody responses are impaired in Inflammatory Bowel Disease patients treated with infliximab, ustekinumab or tofacitinib, but not thiopurines or vedolizumab’ (Presentation no. OP21) was […]
Luis Ostrosky, ACR 2021: Therapeutic Options for COVID-19
TouchIMMUNOLOGY were delighted to talk with Professor Luis Ostrosky (Infectious diseases, UTHealth, Houston, TX, USA) around his presentation titled ‘COVID-19: Update on Therapeutics‘, which was presented at the ACR Convergence, 3-9 November 2021. This information is brought to you by Touch Medical Media and is not sponsored by, nor a part of, the American College […]
Journal articles and more to your inbox
Get the latest clinical insights from touchIMMUNOLOGYSign me up!